AMINO ACID SUBSTITUTED MOLECULES

• US 20080200641A1
• Filed: 04/17/2008
• Published: 08/21/2008
• Est. Priority Date: 05/02/2006
• Status: Active Grant

• Current Assignee: Allozyne, Incorporated (Astrazeneca PLC)
• Original Assignee: Allozyne, Incorporated (Astrazeneca PLC)
• Inventors: Grabstein, Kenneth H., Wang, Aijun, Nairn, Natalie Winblade, Graddis, Thomas James
• Granted Patent: US 7,829,659 B2
• Time in Patent Office: Days
• US Class Current: 528/417
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 1/006 of peptides containing derivatised side chain amino acids
• CPC Class Codes: C07K 1/1077 by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
• CPC Class Codes: C07K 14/565 IFN-beta
• CPC Class Codes: C07K 14/72 for hormones for neuromediators C07K14/70571
• CPC Class Codes: C12P 21/02 having a known sequence of two or more amino acids, e.g. glutathione
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.

Claims

1. A method of modifying a polypeptide containing a non-natural amino acid, comprising incorporating a chemical moiety into said polypeptide by a chemical reaction selected from the group consisting of:

palladium-catalyzed Suzuki coupling, palladium-catalyzed Sonogashira coupling, palladium-catalyzed Heck coupling, palladium-catalyzed Hiyama coupling and Huisgen copper-catalyzed [3+2]cycloaddition, in the presence of micelles or DTT, or both, wherein said modified polypeptide retains its native function.

2. The method of claim 1, further comprising refolding the polypeptide after incorporating the chemical moiety into the polypeptide.

3. The method of claim 1, wherein said micelles comprise SDS.

4. The method of claim 1, wherein said incorporation in the presence of micelles comprises an additional step of freeze/thaw or sonication.

5. The method of claim 1, wherein said incorporation in the presence of DTT occurs in the presence of oxygen and/or TCEP and/or Cu(0).

6. The method of claim 5, wherein said incorporation in the presence of DTT occurs in the presence of oxygen and/or TCEP.

7. The method of claim 6, wherein said incorporation in the presence of DTT occurs in the presence of oxygen.

8. The method of claim 1, wherein said incorporation occurs in the presence of CuBr or CuSO₄.

9. The method of claim 1, wherein said chemical moiety comprises a functional group selected from the group consisting of:

an alkyne, an azide, an alkene, a boronic acid, a silane, an aryl halide, a vinyl halide, and an alkenyl halide,

10. The method of claim 1, wherein said chemical moiety comprises a moiety selected from the group consisting of:

a PEG, a polymer, a water soluble polymer, an oligosaccharide, a toxin, a drug, and a polypeptide.

11. The method of claim 1, wherein the target polypeptide is selected from the group consisting of:

α

-1 antitrypsin, Angiostatin, Antihemolytic factor, an antibody, an antibody fragment, an antibody derivative, a Fab, a Fab′

, a F(ab)₂, a Fd, a Fv, a ScFv, a diabody, a tribody, a tetrabody, a dimer, a trimer, a minibody, an angiogenic molecule, an angiostatic molecule, Apolipoprotein, Apoprotein, Atrial natriuretic factor, Atrial natriuretic polypeptide, an Atrial peptide, a C—

X—

C chemokine, Calcitonin, a CC chemokine, CD40 ligand, C-kit ligand, Chloramphenical acetyltransferase, a Collagen, a Colony stimulating factor, Complement factor 5a, Complement inhibitor, Complement receptor 1, a cytokine, an Epidermal Growth Factor, Erythropoietin, Exfoliating toxins A and B, Factor IX, Factor VII, Factor VIII, Factor X, a Fibroblast Growth Factor, Fibrinogen, Fibronectin, Follitropin, G-CSF, GM-CSF, Glucocerebrosidase, Gonadotropin, growth factor, Hedgehog protein, Hemoglobin, Hepatocyte Growth Factor, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hirudin, Human serum albumin, Human Growth Hormone, Insulin, Insulin-like Growth Factor, GM-CSF, G-CSF, M-CSF, IFN-α

, IFN-β

, IFN-γ

, IFN-Ω

, IFN-τ

, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, Keratinocyte Growth Factor, Lactoferrin, leukemia inhibitory factor, Luciferase, Neurturin, Neutrophil inhibitory factor, oncostatin M, Osteogenic protein, Parathyroid hormone, PD-ECSF, PDGF, peptide hormones, Phenylalanine hydroxylase, Urikase, Pleiotropin, Protein A, Protein G, Pyrogenic exotoxins A, B, and C, Relaxin, Renin, SCF, Soluble complement receptor 1, Soluble I-CAM 1, Soluble interleukin receptors, Soluble TNF receptor, soluble adhesion molecules, Somatomedin, Somatostatin, Somatotropin, Streptokinase, Superantigen, Staphylococcal enterotoxin, Superoxide dismutase, Toll-like receptors, Toxic shock syndrome toxin, Thymosin α

1, Tissue plasminogen activator, Tumor necrosis factor β

, Tumor necrosis factor receptor, Tumor necrosis factor-α

, Vascular Endothelial Growth Factor, a virus-like particle, Urokinase;

a transcriptional modulator that modulates cell growth, differentiation, or regulation, an expression activator, an inflammatory molecule, a growth factor, a growth factor receptor, an oncogene product, FGF, IGF-I, IGF-II, FGF, PDGF, TNF, TGF-α

, TGF-β

, EGF, KGF, SCF/c-Kit, CD40L/CD40, VLA-4/VCAM-1, ICAM-1/LFA-1, hyalurin/CD44, a signal transduction molecule, a transcriptional activator, a transcriptional suppressor, estrogen, progesterone, testosterone, aldosterone, LDL, corticosterone amidase, amino acid racemase, an acylase, a dehalogenase, a dioxygenase, a diarylpropane peroxidase, an epimerase, epoxide hydrolase, an esterase, an isomerase, a kinase, a glucose isomerase, a glycosidase, a glycosyl transferase, a haloperoxidase, a monooxygenase, a lipase, a lignin peroxidase, nitrile hydratase, nitrilase, protease, a phosphatase, subtilisin, a transaminase, and a nuclease.

12. The method of claim 1, wherein said chemical moiety is incorporated by a single, double or triple carbon-carbon linkage between said chemical moiety and said non-natural amino acid residue.

13. The method of claim 1, wherein said chemical moiety is incorporated by a triazole linkage between said chemical moiety and said non-natural amino acid residue.